Fortress Biotech, Inc. - SIC # 2840 -

Ticker Exchange SIC # Website Latest Ticker
FBIO Nasdaq 2840 www.fortressbiotech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Fortress Biotech, Inc.

Mustang Bio Announces Reverse Stock Split - Jan 14th, 2025 1:00 pm
FDA accepts Sentynl’s Menkes disease therapy NDA for priority review - Jan 7th, 2025 11:59 am
Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease - Jan 6th, 2025 1:00 pm
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease - Jan 6th, 2025 1:00 pm
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) - Dec 13th, 2024 11:15 pm
Fortress Biotech Third Quarter 2024 Earnings: Misses Expectations - Nov 17th, 2024 12:25 pm
Fortress Biotech: Q3 Earnings Snapshot - Nov 14th, 2024 10:04 pm
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - Nov 14th, 2024 9:10 pm
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - Nov 14th, 2024 9:05 pm
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - Nov 12th, 2024 9:30 pm
Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - Nov 12th, 2024 9:01 pm
Mustang Bio Receives Positive Listing Determination from Nasdaq - Nov 12th, 2024 1:30 pm
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma - Nov 7th, 2024 1:30 pm
Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea - Nov 4th, 2024 12:00 pm
Fortress Biotech Insiders Placed Bullish Bets Worth US$4.49m - Oct 31st, 2024 10:33 am
Highbridge Capital Management's Strategic Acquisition of Fortress Biotech Shares - Oct 25th, 2024 5:02 pm
Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference - Oct 25th, 2024 12:30 pm
Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds - Oct 24th, 2024 6:10 pm
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit - Oct 9th, 2024 12:30 pm
Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - Oct 3rd, 2024 12:30 pm